
Pirmitegravir
CAS No. 2245231-10-9
Pirmitegravir( —— )
Catalog No. M35151 CAS No. 2245231-10-9
Pirmitegravir (STP0404) is a potent and selective inhibitor of allosteric integrase (ALLINI) targeting the LEDGF/p75 binding site. Pirmitegravir inhibits PBMC.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 207 | Get Quote |
![]() ![]() |
5MG | 321 | Get Quote |
![]() ![]() |
10MG | 519 | Get Quote |
![]() ![]() |
25MG | 1003 | Get Quote |
![]() ![]() |
50MG | 1647 | Get Quote |
![]() ![]() |
100MG | 2151 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NamePirmitegravir
-
NoteResearch use only, not for human use.
-
Brief DescriptionPirmitegravir (STP0404) is a potent and selective inhibitor of allosteric integrase (ALLINI) targeting the LEDGF/p75 binding site. Pirmitegravir inhibits PBMC.
-
DescriptionPirmitegravir is a potent and first-in-class inhibitor of allosteric integrase (ALLINI) that targets LEDGF/p75 binding site. Pirmitegravir displays picomolar IC50 in human PBMCs with a >24,000 therapeutic index against HIV-1. Pirmitegravir harbors outstanding anti-virus and safety properties.
-
In VitroPirmitegravir (Compound STP0404) inhibits dual tropic HIV-189.6 at 1.4 nM IC50 in CEMx174 cells.Pirmitegravir (Compound STP0404) is a highly potent ALLINI with picomolar to single-digit nanomolar IC50 values that inhibits both wild type and Ral-resistant HIV-1 strains.Pirmitegravir (Compound STP0404) displays IC50 of 0.41 nM against HIV-1NL4-3 without observable cytotoxicity in human PBMCs at 10 μM (TC50 >10μM).
-
In VivoPirmitegravir (Compound STP0404) displays appropriate PK profiles for once daily administration.Pirmitegravir (Compound STP0404) lacks micronucleus-inducing and bone marrow cell proliferation inhibitory potentials in rats (500, 1000 and 2000 mg/kg/day), supporting that STP0404 is not genotoxic.Assessment of Pharmacokinetics (PK) profile of Pirmitegravir (Compound STP0404) in rat and dog.Animal Model:SD rats and beagle dogs Dosage:1, 2, 5, and 10 mg/kg Administration:i.v.; p.o.Result:The half-life (T1/2) was 3–7 h, and oral bioavailability (Ft) was 50–93% in these two animal species. Systemic exposure, which was determined by area under the curve and maximum concentration of STP0404 in plasma (AUC and Cmax), increased dose-dependently from 2 to 10 mg/kg.
-
Synonyms——
-
PathwayMicrobiology/Virology
-
TargetHIV
-
RecptorHIV Protease
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2245231-10-9
-
Formula Weight495.01
-
Molecular FormulaC27H31ClN4O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES[C@@H](OC(C)(C)C)(C(O)=O)C=1C(=C2C(N(CC=3C=NN(C)C3)C(C)=C2C)=NC1C)C4=CC=C(Cl)C=C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Maehigashi T, et al. A highly potent and safe pyrrolopyridine-based allosteric HIV-1 integrase inhibitor targeting host LEDGF/p75-integrase interaction site. PLoS Pathog. 2021;17(7):e1009671.
molnova catalog



related products
-
HIV-1 Rev 34-50
HIV-1 Rev (34-50) is a 17-aa peptide derived from the Rev-responsive element (RRE)-binding domains of Rev in HIV-1, with anti-HIV-1 activity. HIV-1 Rev peptide is a one of the cell-penetrating peptides (CPPs) derived from HIV-1 Rev protein residue 34-50. It is a RNA binding peptideand has been used to deliver macromolecules into cells.
-
GSK-8999
GSK-8999 (GSK-2578999) is a novel, potent HIV-1 maturation inhibitor.
-
TERT-IN-1
TERT-IN-1 has anti-HIV activity and can be used to study HIV infection.